梅纳里尼集团向Insilico医学公司发放AI研制的癌症药物许可证,最高可达550万美元。 Menarini Group licenses AI-developed cancer drug from Insilico Medicine for up to $550M.

Menarini Group与Insilico Medicines签订了第二个独家全球许可证协议,为AI发现的针对肿瘤学方面未满足需求的临床前资产提供独家全球许可。 Menarini Group has entered a second exclusive global license agreement with Insilico Medicine for an AI-discovered preclinical asset targeting unmet needs in oncology. 这笔交易包括预付2 000万美元,总价值超过5.5亿美元,外加特许使用费。 The deal includes a $20 million upfront payment, with the total value exceeding $550 million, plus royalties. 该资产是一种针对固态肿瘤的小分子抑制剂,是利用Insilico的人工智能平台开发的,在临床前期测试中显示出了希望。 The asset, a small molecule inhibitor targeting solid tumors, was developed using Insilico's AI platform and has shown promise in preclinical testing.